Investigation of preference, clinical efficacy and trough concentration of vedolizumab by patient-oriented switching to intravenous (IV) or subcutaneous (SC) injection in patients with ulcerative colitis

Investigation of preference, clinical efficacy and trough concentration of vedolizumab by patient-oriented switching to intravenous (IV) or subcutaneous (SC) injection in patients with ulcerative colitis - VIVSC study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054083

Enrollment

Registered

2024-06-07

Start date

2024-06-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with ulcerative coltis who treated or will be treated by vedolizumab

Exclusion criteria

Exclusion criteria: 1. Patients who has allergy to vedolizumab 2. Patients who determined to be inappropriate for this study by physician

Design outcomes

Primary

Measure	Time frame
Selectivity of intraveous or subctaneous injection of vedolizumab	—

Countries

Japan

Contacts

Public ContactShingo Kato

Saitama Medical Center, Saitama Medical University Department of Gastroenterology and Hepatology

skato@saitama-med.ac.jp0492283564

Outcome results